- MCTC Holdings Inc. is a company dedicated to research and development of innovative infusion technologies in the fast-growing area of cannabinoids sciences
- The company recently announced that it is expanding on development infusion technologies to include lesser known cannabinoids such as cannabinol (CBN) and THC-V, which have possible applications in product that promote sleep and control appetite
- MCTC has thus far filed five patents and expects to file at least several additional over the coming months
- The company’s aim is to make the current generation of hemp extract and cannabinoid technologies obsolete
Cannabis infusion technology developer MCTC Holdings Inc. (OTC: MCTC), a Delaware-registered, fully reporting company, is expanding its research beyond the four patents the company has developed with the aim of establishing novel applications of polymeric nanoparticles of cannabinol (CBN) and cannabinoid glycosides.
Since MCTC Holdings reorganized itself in June, the company has focused its corporate efforts on the fast-growing cannabis industry, specifically the development of products that build on proprietary research into exotic cannabinoid isolation, bioenhancement of cannabinoids and polymeric solid nanoparticles and nanofibers that can be added into consumer products and applied through the skin.
“The polymer-based nanoparticles being developed by MCTC significantly differ from the simple oil-in-water nanoemulsions being marketed as interim solutions for the food and beverage industry,” the company stated in a press release (http://cnw.fm/MV8Ao). “The polymer-based particles the Company is developing will allow for significant loading of active ingredients and unparalleled flexibility in creating custom cannabinoid combinations with unique performance characteristics.”
Nanotechnology involves the study of extremely small things, and it is a science that has been used in the food and medicine industries for some time to help humans more effectively utilize the beneficial compounds of food and medicine products. Nanoparticles are directly absorbed into the bloodstream, which allows for a quicker and more effective bio-delivery of their properties than is accomplished through digested substances (http://cnw.fm/d32Nr).
MCTC has been developing nanotechnology’s potential within the cannabis industry, focusing on the potential of microscopic properties in cannabidiol (CBD) by patenting an innovative edible dissolvable film, a water-soluble form of vitamin E, a unique 3D-printed cannabinoid delivery system for beverages, and a broad-property means of dispersing nanoparticles and nanofibers. A fifth patent application is in process.
The company now aims to use its CBD R&D experience in the development of uses for some of the minor cannabinoids, with CBN as the first target. CBN is found only in small amounts and mostly results from oxidation of the other cannabinoids in cannabis, making it difficult to obtain and expensive as a result. But MCTC believes CBN nanoparticles have the potential to deliver the cannabinoid’s beneficial properties in minuscule amounts as an alternative to the volumes used currently for formulation.
MCTC is also researching the potential of cannabinoid glycoside nanoparticles. Glycosides are molecular compounds that involve the binding of a sugar to another compound. Many plants store chemicals in the form of inactive glycosides, and glycosides play numerous important roles in living organisms (http://cnw.fm/L3DeD).
MCTC states that one of its purposes in developing the nanoparticles is for potential use in managing controlled and sustained drug release requirements. For example, several studies indicate CBN may counteract some of the negative effects of other cannabinoids and the creation of particles containing both CBN and other cannabinoids, especially psychoactive cannabinoids, could lead to new opportunities.
As part of the company’s renewed focus on the cannabis industry, MCTC is anticipating a name change to Cannabis Global Inc. in the near future.
For more information, visit the company’s website at www.CannabisGlobalInc.com
NOTE TO INVESTORS: The latest news and updates relating to MCTC are available in the company’s newsroom at http://cnw.fm/MCTC
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
